Best Cardiac and Vascular Disorders Companies in New York City, United States
The 32 best Cardiac and Vascular Disorders companies in New York City, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Everest Medicines.
Ranked: Best Cardiac and Vascular Disorders companies in New York City
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Everest Medicines Developer of drugs for the treatment of cancer | $593M | 77 mo ago | 395 | Kerry Blanchard CEO | Public | — | — |
| 2 | Caladrius Biosciences Developer of cell therapy based drugs for coronary microvascular dysfunction, diabetes, cancer and limbic… | $128M | 69 mo ago | 53 | — | Public | — | — |
| 3 | Applied Therapeutics Developer of drugs for the treatment of metabolic and cardiovascular diseases | $65M | 32 mo ago | 25 | — | Acquired | — | — |
| 4 | Huinno Developer of AI and cloud-based device for cardiac health monitoring and activity tracking | $48M | 58 mo ago | 91 | Yeongjoon Gil Co-Founder & CEO | Series C | — | — |
| 5 | Peerbridge Health Developer of ambulatory ECG system with AI-enabled cardiac diagnostics 42Innovation top 23%Funding top 27%Product top 30%Moat top 39% All 7 signals ▾Innovationtop 23% Fundingtop 27% Producttop 30% Moattop 39% Techtop 48% Globalbottom 37% Marketbottom 19% Innovation: 4 product lines · Deep-tech classification: Tech Hardware Funding: Raised $46.1M across 14 rounds · 14 rounds over 11 yrs (1.3/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $46M | 17 mo ago | 3 | — | Series B | — | — |
| 6 | ARMGO Pharma Developer of small molecule therapeutics to treat debilitating cardiac and vascular disorders | $36M | 19 mo ago | 9 | — | Series B | — | — |
| 7 | Feelmore Labs Online platform offering diverse products, including electronics, fashion, and home goods | $20M | 83 mo ago | 7 | Francois Kress CEO | Series A | — | — |
| 8 | Cibiem Medical device for Carotid Body Modulation. | $10M | 168 mo ago | 3 | — | Series A | 57 patents Endovascular ultrasound-guided ablation catheters for carotid body/sympathetic modulation | — |
| 9 | Axon Therapies Developer of ablation device for heart failure treatment | $7M | 13 mo ago | 18 | Mark Gelfand Co-Founder | Series A | 63 patents Endovascular splanchnic nerve ablation devices for cardiovascular heart failure therapy | — |
| 10 | Proteonomix Developing therapeutics based upon the use of human stem cells and their derivatives to treat cardiac… | $4M | 175 mo ago | 2 | Michael Cohen CEO & President | Deadpooled | 8 patents Stem cell isolation, mobilization, and culture technologies for regenerative medicine. | — |
| 11 | Cornovus Cardioprotective agents for heart failure treatment | $2M | 33 mo ago | — | Bruce T Liang Founder | Deadpooled | — | — |
| 12 | Nanowear Wearable garment based on nanosensor technology for medical monitoring | $2M | 109 mo ago | 22 | — | Seed | 34 patents Nanotech-enabled wearable biomedical sensors for health monitoring and smart wound care | — |
| 13 | Auxilius Pharma Provider of FDA-approved medications for cardiovascular | $1M | 40 mo ago | 6 | — | Seed | — | — |
| 14 | VentriNova Developer of viral vector-based gene therapy for regenerating heart muscle cells | $1M | 206 mo ago | — | Hina Chaudhry Founder | Deadpooled | — | — |
| 15 | SmartEKG Provider of smartphone-based heart monitoring device for patients and providers | $500K | 147 mo ago | — | Benji Strauss Founder & CEO | Deadpooled | — | — |
| 16 | NangioTx Developer of tissue-regenerative peptides for the treatment of peripheral arterial disease | $225K | 79 mo ago | 2 | Vivek Kumar Co-Founder & CEO | Seed | — | — |
Top 12 Cardiac and Vascular Disorders companies in New York City
#1
Series B · New York City, New York · founded 2012 · 3 employees$46.1Mraised▾
Developer of ambulatory ECG system with AI-enabled cardiac diagnostics. The company provides a platform that captures high-fidelity signals, transforming complex data into decision-ready insights. It offers an FDA-cleared wearable device that integrates into existing clinical workflows. The system is designed to enable earlier detection and proactive management of cardiac conditions.
- May 2025Series B$7.2M
- Jun 2024Series B$13.7M
- Feb 2023Series B$5M
- Oct 2022Series B$725K
#2
Series A · New York City, New York · founded 2014 · 18 employees$7Mraised▾
Developer of ablation device for heart failure treatment
- Sep 2025Series A$32M
- Aug 2022Series A$5M
- Apr 2016Series A$2M
#3
Series B · New York City, New York · founded 2004 · 9 employees$36Mraised▾
Developer of small molecule therapeutics to treat debilitating cardiac and vascular disorders. The company's proprietary drug, Rycals, is a new class of oral agents that repair calcium leak through the ryanodine receptor calcium-release channel (RyR), which is located on the sarcoplasmic/endoplasmic reticulum of the cell.
- Mar 2025Grant (prize money)$1M
- Dec 2021Series B$35M
- Aug 2011Seed$1M
#4
Acquired · New York City, New York · founded 2015 · 25 employees$65.2Mraised▾
Developer of drugs for the treatment of metabolic and cardiovascular diseases. The company's product line include AT-007 (govorestat), is a central nervous system-penetrant aldose reductase inhibitor designed for treating rare metabolic disorders such as galactosemia, Charcot-Marie-Tooth Sorbitol Dehydrogenase (CMT-SORD) deficiency, and PMM2-CDG. The company also develops AT-001 (caficrestat), for diabetic cardiomyopathy and diabetic peripheral neuropathy, along with preclinical efforts like AT-003 for diabetic retinopathy.
- Feb 2024Post IPO$100M
- May 2023Post IPO$30M
- Nov 2019Post IPO$20M
- Feb 2019Series B$25M
#5
Public · New York City, New York · founded 2017 · 395 employees$593Mraised▾
Developer of drugs for the treatment of cancer. The company has a portfolio of eight promising drug candidates for oncology, immunology, cardio-renal disease, and infectious disease. The company is developing kinase inhibitors that include FGF401 which is a fibroblast growth factor receptor 4 kinase inhibitor used to treat cancer.
- Jun 2020Series C$260M
- Mar 2020Series C$50M
- 2018Series A$3M
#6
Public · New York City, New York · founded 1980 · 53 employees$128.3Mraised▾
Developer of cell therapy-based drugs for coronary microvascular dysfunction, diabetes, cancer, and limbic ischemia. The company has developed 3 immune-modulating technologies namely - T Regulatory Cell Technology (which infuses polyclonal antibodies to restore the immune balance that is distorted in most cases of autologous and allergic diseases), Tumor Cell / Dendritic Cell Technology (which involves the use of Cancer-Initiating Cells and dendritic cells to mount an immune response) and a CD34 Cell Technology (that involves the transfer of CD34 cells in the bone marrow and peripheral blood for ischemic repair). Its pipeline has cell therapies for type 1 diabetes based on T-regulatory (Treg) cell-based therapy and limbic ischemia (based on CD34 cell technology). The company partners with others to co-develop therapies based on its technologies and also has a subsidiary called PCT, a cell therapy CDMO. Caladrius, in partnership with Invetech, is also developing a closed processing system to increase the level of automation in cell manufacturing processes.
- Jan 2021Post IPO$25M
- Jan 2017Post IPO$6M
- Sep 2016Post IPO$12.6M
- Mar 2016Post IPO$1M
#7
Series C · New York City, New York · founded 2015 · 91 employees$47.6Mraised▾
Developer of AI and cloud-based device for cardiac health monitoring and activity tracking. It provides users with a company that offers electrocardiogram solution that attached to the human body integrated with AI and electrodes for arrhythmia detection.
- Dec 2021Series C$36.5M
- Mar 2020Series A$4.2M
- Aug 2019Series A$6.9M
#8
Deadpooled · New York City, New York · founded 2011$2.1Mraised▾
CORNOVUS Pharmaceuticals is a pharmaceutical company focused on developing cardioprotective agents for late-stage heart failure. The lead compound of the company, MRS2339 is a P2X4 receptor agonist. MRS2339 works by increasing myocardial cyclic guanosine monophosphate (GMP) which likely reflects a consequence of elevated nitric oxide levels(NOs). This molecule is in preclinical stage & the company claims that it has shown promising results.
- Jan 2024Conventional Debt—
- Jan 2024Seed$500K
- Dec 2020Grant (prize money)$1.4M
- Jul 2020Grant (prize money)$2M
#9
Series A · New York City, New York · founded 2018 · 7 employees$20Mraised▾
Online platform offering diverse products, including electronics, fashion, and home goods. It is a comprehensive e-commerce destination with a wide array of categories, from electronics and fashion to home goods and automotive. The platform provides a convenient online shopping experience, featuring categories such as health and beauty, baby and toys, and sports and outdoor equipment. Customers can find various products, including clothing, accessories, home appliances, and personal care items. The site offers features like account management, order tracking, wishlists, and customer support via live chat. It also includes options for returns, cancellations, and multiple payment methods. The platform emphasizes a user-friendly interface with login and registration options, aiming to provide a seamless shopping experience for a broad range of consumer needs.
- Nov 2019Series A$20M
#10
Seed · New York City, New York · founded 2019 · 6 employees$1Mraised▾
Provider of FDA-approved medications for cardiovascular
- Jun 2023Seed$1M
#11
Series A · New York City, New York · founded 2011 · 3 employees$10Mraised▾
Cibiem is a medical device company which offers a proprietary, minimally invasive, catheter-based approach focused on Carotid Body Modulation (CBM) for the treatment of sympathetic nervous system-mediated diseases such as hypertension, heart failure, diabetes and renal failure. The firm is launched out of Coridea which is a New York-based medical device incubator. The company is backed by venture investors Third Rock Ventures and SV Life Sciences.
- Oct 2012Series A$10M
#12
Deadpooled · New York City, New York · founded 1995 · 2 employees$3.8Mraised▾
Proteonomix (formerly National Stem Cell Holding) is focused on developing therapeutics based upon the use of human stem cells and their derivatives. The Proteonomix family of companies includes Proteoderm, StromaCel, PRTMI and Thor Biopharma. StromaCel develops therapeutic modalities for the treatment of cardiovascular disease and for the treatment of patients who have suffered post-myocardial infarction. Proteonomix Regenerative Translational Medicine Institute (PRTMI) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine.
- Mar 2012Series A$3.8M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Cardiac and Vascular Disorders coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.